Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00730483
Other study ID # J0739 CDR0000601054
Secondary ID JHOC-J7039JHOC-N
Status Active, not recruiting
Phase N/A
First received August 7, 2008
Last updated October 1, 2014
Start date February 2009
Est. completion date June 2015

Study information

Verified date October 2014
Source Sidney Kimmel Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor and kill more tumor cells.

PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see how well they work in treating patients with unresectable liver metastases from neuroendocrine tumors.


Description:

OBJECTIVES:

Primary

- To gather preliminary data and determine the feasibility of a randomized study of patients with unresectable hepatic neuroendocrine metastases using PVA microporous hydrospheres/doxorubicin hydrochloride.

OUTLINE: A catheter is placed into the right or left hepatic artery. Patients with unifocal tumors will have the catheter or microcatheter placed more selectively into the 2nd or 3rd order branch off the right or left hepatic artery in closer proximity to the tumor. PVA microporous hydrospheres/doxorubicin hydrochloride mixture is injected into the delivery area.

Patients with less than 75% necrosis at 1 month undergo a second (and possibly a third a month later) chemoembolization.

After completion of study therapy, patients are followed at 1 month, every 2 months for 1 year, and then every 3 months for 1 year.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date June 2015
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

Inclusion criteria:

- Diagnosis of hepatic neuroendocrine metastases not suitable for radical therapies (e.g., resection or liver transplantation)

- Histologically proven neuroendocrine tumor

- Tumors are hypervascular based on visual estimation by investigator

- Predominant to the liver disease, but extrahepatic disease is not an exclusion

- No predominant extrahepatic liver disease

- No significant life-threatening extrahepatic disease, in the judgment of the physician

- Recent-interval progression of hepatic liver metastases

- No diffuse hepatic neuroendocrine metastases defined as massive ill-defined tumor involvement measuring > 90% tumor burden

Exclusion criteria:

- Clinically evident ascites (a radiographic finding of trace ascites on imaging is acceptable)

- Complete occlusion of the entire portal venous system

- Evidence of cirrhosis or portal hypertension

- Vascular resistance peripheral to the feeding arteries precluding passage of PVA microporous hydrospheres/doxorubicin hydrochloride

PATIENT CHARACTERISTICS:

Inclusion criteria:

- ECOG performance status 0-2

- Must have preserved liver function (Child-Pugh class A-B) without significant liver decompensation

- No advanced liver disease (e.g., Child-Pugh C class or active gastrointestinal bleeding, encephalopathy, or ascites [trace ascites is acceptable]), meeting the following criteria:

- Bilirubin > 3 mg/dL

- AST, ALT, and alkaline phosphatase > 5 times upper limit of normal

- Serum creatinine > 2.0 mg/dL

- Albumin = 2.0 g/dL

- No vascular anatomy or blood that precludes catheter placement or emboli injection

- No presence of arteries supplying the lesion not large enough to accept PVA microporous hydrospheres/doxorubicin hydrochloride

- No collateral vessel pathways potentially endangering normal territories during embolization

- No feeding arteries smaller than distal branches from which they emerge

- Not pregnant

Exclusion criteria:

- See Disease Characteristics

- Another active primary tumor

- Any contraindication for hepatic embolization procedures, including any of the following:

- Porto-systemic shunt

- Hepatofugal blood flow

- Impaired clotting tests (i.e., platelet count < 50,000/mm³, INR = 1.8, or PTT = 39 seconds)

- Renal failure

- Severe peripheral vascular disease precluding catheterization

- Any contraindication for doxorubicin hydrochloride administration (i.e., serum bilirubin > 5 mg/dL or leukocyte count < 1,500 cells/mm³)

- Allergy to contrast media

- Intolerant to occlusion procedures

- Presence of end arteries leading directly to cranial nerves

- Presence or likely onset of hemorrhage

- Presence of severe atheromatous disease

PRIOR CONCURRENT THERAPY:

Exclusion criteria:

- Prior anticancer therapy for hepatic neuroendocrine metastases, except previous surgical therapy

- Any continuing complication or prior cancer therapy that has not improved or resolved prior to 21 days before start of treatment, if the investigator determines that the continuing complication will compromise the safety of the patient after treatment with PVA microporous hydrospheres/doxorubicin hydrochloride

- Presence of patent extra-to-intracranial anastomoses or shunts

- Use of PVA microporous hydrospheres/doxorubicin hydrochloride in the following applications:

- Embolization of large-diameter arteriovenous shunts

- Pulmonary arterial vasculature

- Any vasculature where the use of PVA microporous hydrospheres/doxorubicin hydrochloride could pass directly into the internal carotid artery or the above-listed vessels

- Concurrent enrollment in another clinical study

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
PVA microporous hydrospheres/doxorubicin hydrochloride


Locations

Country Name City State
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor response (efficacy) Time to progression No
Primary Safety 30 days post study exit Yes
Secondary Survival overall survival No
Secondary Biochemical response Time to progression No
Secondary Symptomatic response Time to progression No
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Withdrawn NCT00005030 - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Not yet recruiting NCT05981170 - Rurality Adapted Physical Activity Sport Health
Not yet recruiting NCT03058809 - Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood Phase 1/Phase 2
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1
Terminated NCT00918645 - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis N/A
Completed NCT00795678 - Chemotherapeutic Agents in Brain/Breast N/A
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00557102 - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung Phase 2
Recruiting NCT00398437 - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer N/A